Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271998 | 0.87 | LMNA (0.56) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL7440470 | 0.84 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL15677565 | 0.84 | SMN1; SMN2 (0.56) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL8149899 | 0.83 | LMNA (0.59) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL10263314 | 0.81 | SMN1; SMN2 (0.54) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL13741500 | 0.80 | SMN1; SMN2 (0.59) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL4139480 | 0.80 | SMN1; SMN2 (0.52) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL2371661 | 0.80 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL24012570 | 0.79 | LMNA (0.55) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL18002248 | 0.79 | SMN1; SMN2 (0.58) | MEN1KMT2ASMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059611-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-03-17 | — | — | US | disclosed |
| US-6821960-B2 | Glucagon antagonists/inverse agonists | NOYO NORDISK PHARMACEUTICALS, INC. | 2004-11-23 | — | — | US | disclosed |
| EP-1345891-A1 | GLUCAGON ANTAGONIST/INVERSE AGONIST | Novo Nordisk A/S (DK) | 2003-09-24 | — | — | EP | disclosed |
| US-20030027849-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-02-06 | — | — | US | disclosed |
| WO-2002040446-A1 | GLUCAGON ANTAGONIST/INVERSE AGONIST | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040446-A1 | GLUCAGON ANTAGONIST/INVERSE AGONIST | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059611-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MEN1 2605/4885KMT2A 3268/4885SMN1; SMN2 3689/4885 |
| US-20030027849-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MEN1 2605/4885KMT2A 3268/4885SMN1; SMN2 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.